Skip to content

Pain Killer, Anxiety and Mucogingival Therapy

Is Pain Killer Cunsumption Dependent to Anxiety or Mucogingival Therapy?

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05747092
Enrollment
40
Registered
2023-02-28
Start date
2022-01-14
Completion date
2023-06-30
Last updated
2023-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety and Depression

Brief summary

Is the pain killer consumption after gingival treatment related to the level of patient anxiety or to the type of therapy?

Detailed description

Anxiety and depression (HAD) scale used could be reveal the level of the patient anxiety and/or depression before intervention. Additionnaly the use of these specific questionnaires (7 items for anxiety, 7 items for depression) could reveal if the pain killer consumption after gingical treatment is dependant to the level of HAD or to the therapy . This tool (HAD) could allows to recognize, before any (oral)surgery, profil with high risk and propose solution to decrease anxiety and/or depression before treatment.

Interventions

PROCEDUREgingival graft

investigators: Donor site: * tissue graft harvesting from the palate behind the palatal rugae . * placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain. Received site: * Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture. * Test :connective tissue graft using the envelope/pouch technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope

Sponsors

University of Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Intervention model description

group test free gingival graft group control connective tissue graft

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* ASA type I and II subjects * Localized Gingival Recessions * Recessions Cairo RT I-II * FMPS \< 10% * FMBS\< 10% * \<10 cigs/ day * No contra-indication against oral surgical interventions * Patient is able to give inform consent

Exclusion criteria

* Infection (local or systemic). Each infection will be evaluated prior to study procedure for suitability. Patients with gingivitis or local infection (fracture, apical reaction) will undergo a dental treatment prior to his entrance to the study. In case of systemic infection, the evaluation will be based on medical anamneses, and if necessary will be referred to relevant medical tests. * ASA type \> II * Current pregnancy or breastfeeding women * Alcoholism or chronically drug abuse * Smokers, ≳ 10 cigarettes per day * Immunocompromised patients * Uncontrolled diabetes * Untreated periodontitis * History of previous periodontal surgery (mucogingival or other) on the teeth to be included * Presence of severe tooth malposition, rotation or significant version of the tooth to be treated

Design outcomes

Primary

MeasureTime frameDescription
pin killer consumptiontwo weeksthe number of pain killer used after treatment

Countries

Belgium

Contacts

Primary Contactleila Salhi, PhD
l.salhi@chuliege.be0484888091

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026